


# Duna House

Recommendation: Buy

Target price (12M): HUF 4,751 (prev: HUF 4,605)

HUF million	2017 Q4	2016 Q4	Ch (%)
Revenues	1,229	1,160	6%
EBITDA	238	164	45%
EBIT	218	144	52%
Net profit	174	117	49%
EPS	50	34	49%
FY EPS	260	371	-30%
P/E	15	10.6	
No. of transactions (ths)	47.5	42.7	11%



Share price close as of 01/03/2018	HUF 3,960	Bloomberg	DUNAHHOU5 HB
Number of shares [million]	3,4	Reuters	DUNAHOUSE.BU
Market capitalization [HUF mn/EUR mn]	12,856 / 37	Free float	30%
Daily turnover 12M [EUR th]	1.46	52 week range	HUF 3,550-4,400

## Decent Q4 result, profit is expected triple in 2018

### Equity Analyst

Gellert Gaal  
+361 489 2228  
g.gaal@con.hu

50 Alkotás Street,  
Budapest  
www.con.hu

Duna House reported its Q4 and its FY results Wednesday post market. Profit came at HUF 918 million in line with our forecast and adjusted profit (excluding MyCity) arrived into the high end of management guided range HUF 981 million (850-1,000 million). Performance of the core operation in Q4 was decent but investors will focus on the higher dividend (+35% to DPS 176) and on the next year guidance, in our view.

As for **2018 guidance** we can see a huge jump in profit, boosting by the completion of two developments (Reviczky and large part of Forest Hill) reaching HUF 2.8 billion (ca.HUF EPS 810). At the same time, core operation with Metrohouse seems to slightly improve to HUF 1,050 million (mgmt. guidance HUF 950 – 1,150 million) from current HUF 981 million, though this is the weak part of the guidance in our opinion. In nutshell, management guidance is significantly above our expected EPS for 2018 by 26% due to two reasons, which mainly related to developments:

1. We forecasted the completion of project Reviczky in 2017 vs. 2018; and assumed a fully completion of Forest Hill in 2018 vs. management guided 80% (phase 1)
2. We underestimated the profits from the developments by ca. 40%. To remain cautious we assumed ca. 13% profit margin but instead it should hover around 19%.

**On the dividend side**, management propose HUF **DPS 176** dividend for 2018, implying 35% lift compared to last year's meaning a 4.4% dividend yield.

**Core operation:** Q4 result tends to be seasonally weak due to weather reasons, which is reflected in Hungarian EBIT margin (26% vs 33% in Q3) and in MetroHouse's EBIT margin as well (1% vs 4% in Q3). Nevertheless, strong macroeconomic tailwind – transaction volumes up by 11% - has boosted Duna House performance and achieved HUF 238 million EBITDA (+45% y-o-y) and HUF 174 million profit (+49% y-o-y).

On the segment breakdown, there was no huge surprise as we have already observed the preliminary KPI's.


- **Financial intermediary:** The cash cow segment of the group was strong again. Loan intermediation was robust again, loan volume has increased by 57% y-o-y, and pushed EBIT margin to 27% in Q4.
- **Franchise:** Commission from this segment improved by 9% y-o-y thanks to the Hungarian operation which boosted revenues by 15% y-o-y, while Metrohouse dragged down the performance due to lower number of franchise partner on a yearly comparison (79 vs. 74).
- **Own Offices:** Q4 commission was 4.1% lower y-o-y, predominantly due to weak results from Poland.

**Metrohouse:** Overall, we are a bit disappointed about the financial performance of Metro House as the operation added only HUF 20 million (2% EBIT margin) to the group total EBIT. If this trend continues in 2018 we might adjust our earnings forecast for the Polish operation, pushing the expected EBIT convergence one year later, which would lower our valuation for Metrohouse by HUF 100-150 million (43 per share).

**Positive momentum continues for transactions.** Total number of transaction came 3% above compared to 2016 and reached 148,896 based on DH's estimation. Which positive trend should continue as loose monetary conditions increasing wages and large number of new house completions this year should continue to fuel the momentum and lift the number of transactions higher in our view. In this respect, DH has already published its January estimation and it was 5% higher than last year which underpins our positive stance. What is more, management in its guidance shared its positive view on the economy as a whole and on the real estate market for 2018. They

expect 15% more transactions, 5-10% house price increase, and bit moderated 15-20% loan volume growth than in 2017.


**Monthly transaction number according to DH's estimation**



Source: Company reports

**Opinion:** Duna House surprised us with strong result on developments which prompted us to revalue that business arm of the group, and thus lifted our price target by 3% to HUF 4,751 from HUF 4,605 predominantly because of the higher profit on projects Forest Hill and Reviczky (HUF 658 per share from HUF 492 per share). We would like to highlight that we remain cautious regarding the third development project and still assuming 13% profit margin with the value of 64 per share, as that project was started later with presumably at an inflated costs level. As for the core operation, Hungarian core was robust again boosted by strong loan volumes, but Metrohouse was meagre. With the new price target we see 19% upside in Duna House.

**Sum of part Valuation**



Source: Concorde Estimates

### Quarterly P&L

	Q4 2017	Q4 2016	Ch (%)
<b>Revenue</b>	<b>1,229</b>	<b>1,160</b>	<b>6%</b>
Operating revenue	1,195	1,070	12%
Other income	33	90	-63%
<b>OPEX</b>	<b>1,011</b>	<b>1,017</b>	<b>-1%</b>
Cost of materials	19	19	-3%
Cost of sold goods and services	241	274	-12%
Used services	1,285	484	165%
Personnel expenses	154	146	5%
Depreciation and amortization	20	20	-1%
Other operating expenses	-708	73	-1072%
<b>EBITDA</b>	<b>238</b>	<b>164</b>	<b>45%</b>
<b>EBIT</b>	<b>218</b>	<b>144</b>	<b>52%</b>
Financial income	9	3	229%
Financial expense	21	19	7%
Revaluation	1	39	-98%
EBT	206	166	24%
Income tax expense	-33	24	-235%
Other	0	25	-100%
Non-controlling interests	0	1	-146%
<b>Net income</b>	<b>174</b>	<b>117</b>	<b>49%</b>
Transaction Number	47,492	42,744	11%
EPS	50	34	
EBIT margin	18%	12%	

Source: company reports

**Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts certification and other important disclosures, please refer to the “Disclaimer” section at the end of this report.**

#### **DISCLAIMER 1.**

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country’s jurisdiction. For important disclosures to U.S. investors, please refer of the “Notice to U.S. Investors” section at the end of this Disclaimer.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm’s capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients’ behalf in strict compliance with the Hungarian Capital Markets Act.

#### *ANALYSTS CERTIFICATION*

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts’ compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter’s exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

*EXPLANATION OF RATINGS AND METHODOLOGY*

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10%-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if covering analyst considers new information may change the valuation materially and if this may take more time.
Coverage in transition	Coverage in transition rating is assigned to a stock if there is a change in analyst.

**Securities prices:**

Prices are taken as of the previous day's close on the home market unless otherwise stated.

**Valuations and risks:**

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at [Rating Methodology](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038) on our website. ([https://www.con.hu/wp-content/uploads/2016/04/Methodology\\_concorde\\_research.pdf?tstamp=201710021038](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038))

**Research disclosures:**

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at [Rating history](https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038). (<https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038>)

*GENERAL*

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

**NOTICE TO US INVESTORS**

This report was prepared, approved, published and distributed Concorde Securities Ltd. located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by LXM LLP USA, a U.S. registered broker dealer, on behalf of Concorde Securities Ltd. only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through LXM LLP USA.

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

Analyst Certification. Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. Please bear in mind that (i) Concorde Securities Ltd. is the employer of the research analyst(s) responsible for the content of this report and (ii) research analysts preparing this report are resident outside the United States and are not associated persons of any US regulated broker-dealer and that therefore the analyst(s) is/are not subject to supervision by a US broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Important US Regulatory Disclosures on Subject Companies. This material was produced by Concorde Securities Ltd. solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by LXM LLP USA and elsewhere in the world by Concorde Securities Ltd. or an authorized affiliate Concorde Securities Ltd. This document does not constitute an offer of, or an invitation by or on behalf of Concorde Securities Ltd. or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which Concorde Securities Ltd. or its Affiliates consider to be reliable. None of Concorde Securities Ltd. accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

LXM LLP USA assumes responsibility for the research reports content in regards to research distributed in the U.S. LXM LLP USA or its affiliates has not managed or co-managed a public offering of securities for the subject company in the past 12 months, has not received compensation for investment banking services from the subject company in the past 12 months, does not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next 3 months. LXM LLP USA has never owned any class of equity securities of the subject company. There are not any other actual, material conflicts of interest of LXM LLP USA at the time of the publication of this research report. As of the publication of this report LXM LLP USA, does not make a market in the subject securities.

## **DISCLAIMER 2.**

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.